Seroatlas · Human Serome Atlas

SLC52A2

Solute carrier family 52, riboflavin transporter, member 2

Also known as: D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2, S52A2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9HAB3
Gene
SLC52A2
Ensembl
ENSG00000185803
Chromosome
8
Canonical length
445 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene encodes a membrane protein which belongs to the riboflavin transporter family. In humans, riboflavin must be obtained by intestinal absorption because it cannot be synthesized by the body. The water-soluble vitamin riboflavin is processed to the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) which then act as intermediaries in many cellular metabolic reactions. Paralogous members of the riboflavin transporter gene family are located on chromosomes 17 and 20. Unlike other members of this family, this gene has higher expression in brain tissue than small intestine. Alternative splicing of this gene results in multiple transcript variants encoding the same protein. Mutations in this gene have been associated with Brown-Vialetto-Van Laere syndrome 2 - an autosomal recessive progressive neurologic disorder characterized by deafness, bulbar dysfunction, and axial and limb hypotonia. [provided by RefSeq, Jul 2012]

Canonical amino-acid sequenceUniProt

445 residues, UniProt reviewed canonical sequence.

>Q9HAB3|SLC52A2
     1  MAAPTPARPV LTHLLVALFG MGSWAAVNGI WVELPVVVKE LPEGWSLPSY VSVLVALGNL
    61  GLLVVTLWRR LAPGKDEQVP IRVVQVLGMV GTALLASLWH HVAPVAGQLH SVAFLALAFV
   121  LALACCASNV TFLPFLSHLP PRFLRSFFLG QGLSALLPCV LALVQGVGRL ECPPAPINGT
   181  PGPPLDFLER FPASTFFWAL TALLVASAAA FQGLLLLLPP PPSVPTGELG SGLQVGAPGA
   241  EEEVEESSPL QEPPSQAAGT TPGPDPKAYQ LLSARSACLL GLLAATNALT NGVLPAVQSF
   301  SCLPYGRLAY HLAVVLGSAA NPLACFLAMG VLCRSLAGLG GLSLLGVFCG GYLMALAVLS
   361  PCPPLVGTSA GVVLVVLSWV LCLGVFSYVK VAASSLLHGG GRPALLAAGV AIQVGSLLGA
   421  VAMFPPTSIY HVFHSRKDCA DPCDS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC52A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
11
Mean surface accessibility (rSASA)
0.31
Highest tissue expression
34 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 34 nTPM
  • pancreas: 33 nTPM
  • colon: 27 nTPM
  • esophagus: 27 nTPM
  • spleen: 26 nTPM
  • testis: 25 nTPM

Single-cell type

  • other brain neurons: 15 nCPM
  • brain excitatory neurons: 13 nCPM
  • brain inhibitory neurons: 9.2 nCPM
  • papillary tip epithelial cells: 9.1 nCPM
  • oligodendrocyte progenitor cells: 8 nCPM
  • renal collecting duct principal cells: 7.8 nCPM

Immune cell

  • naive B-cell: 9.9 nTPM
  • eosinophil: 9.2 nTPM
  • non-classical monocyte: 7.6 nTPM
  • plasmacytoid DC: 7.6 nTPM
  • intermediate monocyte: 5.9 nTPM
  • T-reg: 5.7 nTPM

Brain region

  • cerebellum: 12 nTPM
  • hypothalamus: 12 nTPM
  • midbrain: 12 nTPM
  • medulla oblongata: 12 nTPM
  • pons: 11 nTPM
  • thalamus: 11 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC52A2.

Disease | AllUniProt

Conditions SLC52A2 is implicated in, by any mechanism.

Disease | GeneticClinVar

43 pathogenic / likely-pathogenic of 572 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on SLC52A2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.98
gnomAD pLI
0
gnomAD missense Z
-0.85
DepMap mean gene effect
-0.13
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 16% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC52A2 as an antibody target. Whether an autoantibody or antibody against SLC52A2 could matter depends on whether native SLC52A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC52A2 is annotated at the cell surface, where native SLC52A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC52A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC52A2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...